252 related articles for article (PubMed ID: 18223359)
1. Follow-on drugs and indications: the importance of incremental innovation to medical practice.
Cohen J; Kaitin K
Am J Ther; 2008; 15(1):89-91. PubMed ID: 18223359
[No Abstract] [Full Text] [Related]
2. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
3. Aligning pharmaceutical innovation with medical need.
Nathan C
Nat Med; 2007 Mar; 13(3):304-8. PubMed ID: 17342145
[No Abstract] [Full Text] [Related]
4. Clinical research in China and India: a paradigm shift in drug development.
Singh R
Drug Discov Today; 2006 Aug; 11(15-16):675-6. PubMed ID: 16846793
[No Abstract] [Full Text] [Related]
5. Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.
Adam M
Stud Hist Philos Biol Biomed Sci; 2005 Sep; 36(3):513-37. PubMed ID: 16137601
[TBL] [Abstract][Full Text] [Related]
6. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
7. Drug discovery alliances.
Jones A; Clifford L
Nat Rev Drug Discov; 2005 Oct; 4(10):807-8. PubMed ID: 16237845
[No Abstract] [Full Text] [Related]
8. [Structured introduction of new drug therapies: valuable initiative--transparency required].
Lundkvist J; Henriksson F
Lakartidningen; 2009 Jan 7-13; 106(1-2):51. PubMed ID: 19235324
[No Abstract] [Full Text] [Related]
9. Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories.
Miller GA
IDrugs; 2007 Mar; 10(3):181-4. PubMed ID: 17351872
[TBL] [Abstract][Full Text] [Related]
10. Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS
J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
[No Abstract] [Full Text] [Related]
11. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
12. Productivity counts--but the definition is key.
Mervis J
Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
[No Abstract] [Full Text] [Related]
13. The large scale restructuring of pharmaceutical company research function. Preface.
Lawton G; Witty DR
Prog Med Chem; 2012; 51():v-vi. PubMed ID: 22520474
[No Abstract] [Full Text] [Related]
14. Recruiters and industry.
Jackson M
Nature; 2004 Mar; 428(6981):450. PubMed ID: 15042100
[No Abstract] [Full Text] [Related]
15. Recent patent applications in angiogenesis research.
Nat Biotechnol; 2006 Feb; 24(2):155. PubMed ID: 16465155
[No Abstract] [Full Text] [Related]
16. Commercial interest waxes for IGF-1 blockers.
Osborne R
Nat Biotechnol; 2008 Jul; 26(7):719-20. PubMed ID: 18612276
[No Abstract] [Full Text] [Related]
17. Big Pharma's Commedia.
Steele FR
Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
[No Abstract] [Full Text] [Related]
18. Analysis of labeling decisions regarding therapeutic indications during new drug application reviews in Japan.
Yokota M; Kusama M; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2011 Sep; 90(3):432-41. PubMed ID: 21814198
[TBL] [Abstract][Full Text] [Related]
19. [Fewer new drugs from drug industry].
Reikvam A
Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3106-7. PubMed ID: 18049505
[No Abstract] [Full Text] [Related]
20. Obstacles and opportunities in new drug development.
Kaitin KI
Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
[No Abstract] [Full Text] [Related]
[Next] [New Search]
